Drug Profile

OMS 1029

Alternative Names: anti-MASP-2 antibody; OMS-1029

Latest Information Update: 23 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Omeros Corporation
Class Anti-inflammatories; Monoclonal antibodies
Mechanism of Action MASP2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Wet age-related macular degeneration

Most Recent Events

23 Sep 2025 OMS 1029 is still in phase-I clinical development in Wet age related macular degeneration (In volunteers) in USA (IV) (SC) (Omeros Corporation pipeline, September 2025)
07 Aug 2024 Omeros Corporation plans a phase II trial for Wet age related macular degeneration
15 Feb 2024 Omeros Corporation has a multiple patent protection for OMS 1029 in USA and world-wide before February 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com